When pharma companies grow cells to make biologic drugs, they spend months guessing which cells will perform best at factory scale. It's like auditioning thousands of singers in a living room and hoping they'll still sound great in a stadium. BIOSIM built a chemical stress-test kit that simulates factory conditions on a lab bench, so you know which cells will thrive before you scale up. The result: what used to take 16 months and €2.3 million now takes 6 months and €1.1 million.
Biopharmaceutical companies spend 16 months and €2.3 million on average just to develop the right cell line for each biologic drug — and they often discover problems only after scaling up to manufacturing. In a market worth over €500 billion and growing at 8% annually, this bottleneck delays patient access and inflates drug costs.
Valitacell built ChemStress, a CE-marked analytical platform that uses chemical stress tests to predict how cells will perform in large-scale bioreactors. The project delivered a validated, productized version demonstrated at 4 biopharma manufacturing sites, with peer-reviewed results and a customer-endorsed value proposition.
If you are a CDMO handling cell line development for multiple clients — this project developed ChemStress, a chemical stress-testing platform demonstrated at 4 leading biopharma manufacturing sites. It cuts cell line development from 16 to 6 months and cost from €2.3 million to €1.1 million per program, letting you take on more projects per year with faster turnaround.
If you are a vaccine manufacturer racing to scale new biologics — this project created a CE-marked testing platform that predicts which cell lines will perform best in large-scale bioreactors. Instead of discovering problems at manufacturing scale, you catch them early. The technology was validated with market leaders including GE Healthcare and MedImmune.
If you are an SME developing biosimilar drugs and need to keep development costs competitive — this project built a platform that reduces cell line development cost from €2.3 million to €1.1 million. For smaller companies, cutting that single stage by over 50% can make the difference between a viable product and an abandoned pipeline.
Based on project data, ChemStress reduces the cell line development stage cost from €2.3 million to €1.1 million — a saving of €1.2 million per program. It also cuts the timeline from 16 months to 6 months, freeing capacity for additional programs.
Yes. BIOSIM included demonstration of ChemStress at 4 leading biopharmaceutical manufacturing sites. The project deliverables included a cross-site review to determine the final product model. Valitacell was already a validated supplier to GE Healthcare and MedImmune before the project.
Valitacell is the sole partner and owner of the ChemStress technology. As an SME with 100% industry consortium, the IP sits entirely with the company. The product achieved CE marking as part of the project deliverables, indicating a commercialized product rather than a licensed technology.
This is a market-ready product. The project was an SME Instrument Phase 2 grant focused on commercialization, not basic research. Deliverables included a CE-marked product and preparation for sales and marketing launch. Valitacell was already selling to the market before the project began.
Based on available project data, ChemStress is an analytical platform used during the cell line development stage — before manufacturing begins. It simulates manufacturing stresses using small molecule chemicals at lab scale, so it integrates into your existing development workflow without modifying your production line.
The ChemStress platform is CE marked, and the project specifically aimed to provide greater regulatory confidence. By predicting cell performance under manufacturing conditions early, it reduces the risk of late-stage failures that can trigger regulatory delays. Results were submitted for peer-reviewed publication.
Valitacell Ltd is an Irish SME that was already an established supplier to major biopharma companies including GE Healthcare and MedImmune. The project projected €40 million in end-user product sales and 50 jobs within 5 years post-project. Their website is valitacell.com.
This is a single-company project: Valitacell Ltd, an Irish SME that received the full €2,029,325 under the SME Instrument Phase 2 scheme. The 100% industry, 100% SME composition signals a commercially driven venture — no academic partners means the focus was entirely on bringing an existing technology to market, not fundamental research. Valitacell already had validated relationships with major buyers like GE Healthcare and MedImmune, which adds commercial credibility. The lack of consortium diversity is actually a strength here: one company, one product, one clear path to market.
Valitacell Ltd (Ireland) — contact via their website valitacell.com or request introduction through SciTransfer
Want to explore how ChemStress could cut your cell line development costs by 50%? SciTransfer can arrange a direct introduction to the Valitacell team with a tailored briefing for your pipeline.
